Baseline differences in the SAVOR trial

Diabetes Obes Metab. 2015 Dec;17(12):1202. doi: 10.1111/dom.12505. Epub 2015 Jul 8.

Authors

H J Luijendijk¹, T A Hulshof¹

Affiliation

¹ Department of General Practice, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

PMID: 26094750
DOI: 10.1111/dom.12505

No abstract available

Publication types

Letter

MeSH terms

Adamantane / adverse effects
Adamantane / analogs & derivatives*
Adamantane / therapeutic use
Biomedical Research
Diabetes Complications / chemically induced
Diabetes Complications / epidemiology
Diabetes Complications / mortality
Diabetes Complications / prevention & control
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / mortality
Dipeptides / adverse effects*
Dipeptides / therapeutic use
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
Humans
Randomized Controlled Trials as Topic
Research Design
Risk
Selection Bias
United States
United States Food and Drug Administration

Substances

Dipeptides
Dipeptidyl-Peptidase IV Inhibitors
saxagliptin
Adamantane